Related Experiment Video
Updated: May 28, 2025

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Dysregulation of the p300/CBP histone acetyltransferases in human cancer
Longxia Xu1, Hongwen Xuan1, Xiaobing Shi1
1Department of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.
Abstract:
p300 (E1A binding protein 300) and CBP (CREB-binding protein) are critical regulators of chromatin dynamics and gene expression, playing essential roles in various cellular processes, including proliferation, differentiation, apoptosis, and immune responses. These homologous histone acetyltransferases (HATs) function as transcriptional co-activators by acetylating histones and non-histone proteins. p300/CBP is essential for development, and dysregulation of p300 and CBP has been implicated in several human diseases, particularly cancer. Somatic mutations that inactivate p300/CBP are frequently observed across various cancer types. Additionally, other mutations leading to translocations or truncations of p300/CBP can result in enhanced catalytic activity, potentially representing novel gain-of-function mutations that promote tumor progression. In this review, we discuss the mechanisms underlying the regulation of p300/CBP HAT activity, its dysregulation in cancer, and the development of p300/CBP inhibitors and their potential in cancer therapies.
Insights
p300 and CREB-binding protein (CBP) are crucial for gene expression and development. Their dysregulation in cancer, through mutations, drives tumor progression, highlighting their therapeutic potential.
Area of Science:
- Molecular Biology
- Epigenetics
- Cancer Biology
Background:
- p300 (E1A binding protein 300) and CBP (CREB-binding protein) are homologous histone acetyltransferases (HATs).
- They act as transcriptional co-activators, regulating gene expression and cellular processes like proliferation and differentiation.
- p300/CBP function is vital for normal development.
Purpose of the Study:
- To review the regulatory mechanisms of p300/CBP HAT activity.
- To discuss the role of p300/CBP dysregulation in cancer development.
- To explore the therapeutic potential of p300/CBP inhibitors in cancer treatment.
Main Methods:
- Review of existing literature on p300/CBP function, regulation, and involvement in cancer.
- Analysis of somatic mutations affecting p300/CBP activity in various cancer types.
- Discussion of emerging therapeutic strategies targeting p300/CBP.
Main Results:
- Somatic mutations inactivating p300/CBP are common in cancers.
- Translocations or truncations can lead to gain-of-function mutations, promoting tumor progression.
- p300/CBP HAT activity is tightly regulated, and its dysregulation contributes to oncogenesis.
Conclusions:
- p300/CBP are critical regulators whose dysregulation is implicated in cancer.
- Understanding p300/CBP mechanisms offers insights into cancer development.
- Inhibitors targeting p300/CBP represent a promising avenue for cancer therapy.
More Related Videos
Related Concept Videos
Spreading of Chromatin Modifications
Writers
The writer...
Epigenetic Regulation
X-chromosome...
Abnormal Proliferation
Histone Variants at the Centromere
Master Transcription Regulators
Heterochromatin
Constitutive heterochromatin: It is a highly compact region of chromatin that is mostly concentrated in the centromere and telomere. Unlike euchromatin, the amino acid at...

